These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34027668)

  • 1. Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
    Huang B; Wang H; Zheng Y; Li M; Kang G; Barreto-de-Souza V; Nassehi N; Knapp PE; Selley DE; Hauser KF; Zhang Y
    J Med Chem; 2021 Jun; 64(11):7702-7723. PubMed ID: 34027668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
    Arnatt CK; Falls BA; Yuan Y; Raborg TJ; Masvekar RR; El-Hage N; Selley DE; Nicola AV; Knapp PE; Hauser KF; Zhang Y
    Bioorg Med Chem; 2016 Nov; 24(22):5969-5987. PubMed ID: 27720326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.
    Yuan Y; Arnatt CK; Li G; Haney KM; Ding D; Jacob JC; Selley DE; Zhang Y
    Org Biomol Chem; 2012 Apr; 10(13):2633-46. PubMed ID: 22354464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
    El-Hage N; Dever SM; Podhaizer EM; Arnatt CK; Zhang Y; Hauser KF
    AIDS; 2013 Sep; 27(14):2181-90. PubMed ID: 23751259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
    Yuan Y; Arnatt CK; El-Hage N; Dever SM; Jacob JC; Selley DE; Hauser KF; Zhang Y
    Medchemcomm; 2013 May; 4(5):847-851. PubMed ID: 23682308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CB-0821, a novel CC chemokine receptor 5 (CCR5) inhibitor with improved binding efficacy proposed as anti-HIV candidate: Computational and in vitro approach.
    Kumar A
    Biotechnol Appl Biochem; 2024 Aug; 71(4):849-859. PubMed ID: 38556770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Virtual Screening Approach to Predict Novel Natural Compounds against HIV-1 CCR5.
    Eid AM; Selim A; Khaled M; Elfiky AA
    J Phys Chem B; 2024 Jul; 128(29):7086-7101. PubMed ID: 39016126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
    Szabo I; Wetzel MA; Zhang N; Steele AD; Kaminsky DE; Chen C; Liu-Chen LY; Bednar F; Henderson EE; Howard OM; Oppenheim JJ; Rogers TJ
    J Leukoc Biol; 2003 Dec; 74(6):1074-82. PubMed ID: 12972507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates.
    Kim S; Hahn YK; Podhaizer EM; McLane VD; Zou S; Hauser KF; Knapp PE
    J Neuroinflammation; 2018 Oct; 15(1):285. PubMed ID: 30305110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
    Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
    J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV co-receptor CCR5: structure and interactions with inhibitors.
    Wang T; Duan Y
    Infect Disord Drug Targets; 2009 Jun; 9(3):279-88. PubMed ID: 19519482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
    Nakata H; Maeda K; Das D; Chang SB; Matsuda K; Rao KV; Harada S; Yoshimura K; Ghosh AK; Mitsuya H
    Sci Rep; 2019 Mar; 9(1):4828. PubMed ID: 30886166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5.
    Song C; Rahim RT; Davey PC; Bednar F; Bardi G; Zhang L; Zhang N; Oppenheim JJ; Rogers TJ
    J Biol Chem; 2011 Jun; 286(23):20354-65. PubMed ID: 21454526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.